Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Mankind Pharma and other domestic companies have launched generic versions of the popular diabetes drug Empagliflozin at ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...

Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

Glenmark and Alkem Labs launched the generic version as well as its Fixed Dose Combination (FDCs) of Empagliflozin in India.

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.

Empagliflozin is effective in improving the clinical outcomes in patients with acute heart failure and low BP without further ...

Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly ...

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...

Mankind Pharma launches affordable empagliflozin in India for diabetes: Our Bureau, Mumbai Thursday, March 13, 2025, 17:30 Hrs [IST] Mankind Pharma has launched its affordable gen ...

Prices of key anti-diabetic drug empagliflozin crashed by as much as 90 per cent to ₹5.5 per tablet as several pharma ...